Construction and application of rational drug use system for patients with abnormal liver function

ZHANG Lei; CAI Wenxi; YANG Bo; WEN Jian; LIU Xinlin

PDF(1046 KB)

Medical Journal of the Chinese People Armed Police Forces ›› 2022, Vol. 33 ›› Issue (11) : 921-923.

Construction and application of rational drug use system for patients with abnormal liver function

ZHANG Lei¹, CAI Wenxi¹, YANG Bo¹, WEN Jian², LIU Xinlin³

Author information +

History +

Abstract

Objective To introduce the function and operation of rational drug use system for patients with abnormal liver function (hepatitis B patients). Methods The system was established by SPRING C/S frame, and then the hepatitis B patients drug use information from January to August 2021 was evaluated. Results The system provided 1562 pieces of rational drug use suggestions, and doctors received 1138 pieces, accounting for 72.85%. The rational drug use rate of patients with abnormal liver function increased month by month, reaching 77% in August 2021, which was significantly higher than that in January (58%). Conclusions This system can provide doctors with rational dosage of drugs on the basis of liver function, so that the rational drug use can be achieved.

Key words

abnormal liver function / rational drug use / dosage of drug

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

ZHANG Lei, CAI Wenxi, YANG Bo, WEN Jian, LIU Xinlin. Construction and application of rational drug use system for patients with abnormal liver function[J]. Medical Journal of the Chinese People Armed Police Forces. 2022, 33(11): 921-923

References

[1] 谢渭芬,王剑.我国肝病研究40年回眸与展望[J].中华消化杂志,2021,41(12):793-797.
[2] 王桂爽,谢雯,万钢,等.某综合医院15年间肝病住院患者疾病谱变化分析[J].中华实验和临床感染病杂志,2021,15(1):29-36.
[3] 余文豪,刘汶.药物性肝病研究进展[J].中国中西医结合消化杂志,2020,28(5):398-401.
[4] 力竟成.基于SPRING的三层C/S架构门诊系统的设计[J].硅谷,2011,19:62-8.
[5] 张耀弟.CTP评分评估肝硬化患者短期预后的价值分析[J].甘肃科技,2020,36(9):117-118.
[6] 陈健,钱建清,徐晓丹,等.Child-Turcotte-Pugh评分差值对肝硬化患者短期预后的预测价值[J]. 国际消化病杂志,2019,39(3):198-201.
[7] 支艳俊.100例妊娠期肝功能异常患者的临床分析[J].临床与病理杂志,2022,42(4):841-846.
[8] 史秀梅,胡永领,谢士宁,等.临床药学监护对肝功能损害患者疗效及用药安全性的影响[J].贵州医药,2019,43(7):1160-1161.
[9] 陆光洁,白晓黎,翟晓雨,等.临床药学监护在肝功能损害患者中的应用效果[J].中国民康医学,2021,33,(20):144-147.
[10] 鞠引,金文娟.2016-2019年住院肝功能异常患者病因分析[J].智慧健康,2021,7(29):103-106.
[11] 徐玉.浅谈肝功能不全患者用药个体化[J].中国实用医药,2008,3(6):77-78.
[12] 刘苏利,吴寅,侯晓叶,等.295例患者的抗菌药物不良反应分析及减少药源性损害措施的探讨[J].临床医学研究与实践,2021,6(17):20-23.
[13] TornioA,Backmanj T.Cytochrome P450 in pharmacogenetics: an update[J].Adv Pharmacol(San Diego, Calif),2018,83(3):29-32.
[14] 李飞,陆伦根.肝功能异常的评估及临床意义[J].临床肝胆病杂志,2015,31(9):1543-1546.
[15] 陈建丽.肝炎肝硬化患者的肝功能检测结果分析及其临床指导价值[J].吉林医学,2022,43(3):808-811.